January 17, 2025

FDA Approves Datopotamab Deruxtecan-dlnk for Advanced HR-Positive, HER2-Negative Breast Cancer

Today, the FDA approved a TROP-2–directed antibody and topoisomerase inhibitor conjugate for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer ...

The ASCO Post

January 17, 2025

FDA Chief Warns of Online Drug Risks

Outgoing FDA Commissioner raises concerns about safety of online-purchased compounded weight loss meds, highlighting challenges faced by the FDA, amidst contrasting views from nominee for Health and Human Services Secretary.

Reuters

January 17, 2025

Trial: High-Dose Semaglutide Cuts Weight 20.7%

Novo Nordisk's high-dose semaglutide trial demonstrates a 20.7% weight reduction in overweight patients with obesity, promising new advancements in the treatment of obesity and diabetes.

Reuters

January 17, 2025

CDC Urges 24-Hour Bird Flu Tests

The CDC emphasizes timely testing for avian influenza A in hospitalized patients to prevent delays and enhance rapid public health responses. Low person-to-person transmission risk has been reported with ongoing U.S. cases among farmworkers.

Reuters

January 17, 2025

FDA Approves KRAS Combo for CRC

The approval is based on results from the CodeBreaK 300 clinical trial, a randomized, open-label study that evaluated the safety and efficacy of combining sotorasib with panitumumab.

Conexiant

January 16, 2025

USPSTF Adds Health Equity, Maternal Care Experts

New members, Alicia Fernandez, MD, and Ericka Gibson, MD, MPH, bring expertise in health equity and maternal health care to the U.S. Preventive Services Task Force, contributing to evidence-based recommendations about clinical preventive services such as screenings, and counseling services.

Conexiant

January 16, 2025

FDA Clears First Nicotine Pouches for U.S. Market

FDA grants first-ever marketing authorization for ZYN nicotine pouches following a scientific review that showed lower health risks compared to traditional tobacco products and minimal youth usage.

Conexiant

January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

FDA to Revoke Red No. 3

Red No. 3 is found in many popular food items, including Pop Tarts, Dole Fruit Packs, Double Bubble Gum, Peeps, and more.

Conexiant